MapLight Therapeutics, Inc.
ML-055
neuropsychiatric disorders
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ML-055 in neuropsychiatric disorders are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Nominate preclinical candidate in 2026”